148 related articles for article (PubMed ID: 32672481)
1. Subventricular zone contacting glioblastoma: tumor size, molecular biological factors and patient survival.
Hallaert G; Pinson H; Van den Broecke C; Vanhauwaert D; Van Roost D; Boterberg T; Kalala JP
Acta Oncol; 2020 Dec; 59(12):1474-1479. PubMed ID: 32672481
[TBL] [Abstract][Full Text] [Related]
2. MR Imaging, MGMT Promoter Methylation Features and Prognostic Analysis of Subventricular Zone Contacting IDH Wild-type Glioblastoma.
Liu R; Liu Q; Zhao K; Liu M; Sun G; Xu B
Curr Med Imaging; 2023; 19(12):1378-1386. PubMed ID: 36694322
[TBL] [Abstract][Full Text] [Related]
3. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
5. Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns.
Comas S; Luguera E; Molero J; Balaña C; Estival A; Castañer S; Carrato C; Hostalot C; Teixidor P; Villà S
Clin Transl Oncol; 2021 Mar; 23(3):554-564. PubMed ID: 32728970
[TBL] [Abstract][Full Text] [Related]
6. Clinical correlates of subventricular zone-contacting glioblastomas: a meta-analysis.
Mistry AM
J Neurosurg Sci; 2019 Oct; 63(5):581-587. PubMed ID: 29205011
[TBL] [Abstract][Full Text] [Related]
7. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
8. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
9. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
11. Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.
Hallaert G; Pinson H; Van den Broecke C; Sweldens C; Van Roost D; Kalala JP; Boterberg T
Acta Oncol; 2021 May; 60(5):613-619. PubMed ID: 33689536
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
13. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
14. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
15. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
16. Influence of wide opening of the lateral ventricle on survival for supratentorial glioblastoma patients with radiotherapy and concomitant temozolomide-based chemotherapy.
Saito T; Muragaki Y; Maruyama T; Komori T; Nitta M; Tsuzuki S; Fukui A; Kawamata T
Neurosurg Rev; 2020 Dec; 43(6):1583-1593. PubMed ID: 31705405
[TBL] [Abstract][Full Text] [Related]
17. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
18. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
Shu C; Wang Q; Yan X; Wang J
Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
[TBL] [Abstract][Full Text] [Related]
19. What is the role of the subventricular zone in radiotherapy of glioblastoma patients?
Bender K; Träger M; Wahner H; Onken J; Scheel M; Beck M; Ehret F; Budach V; Kaul D
Radiother Oncol; 2021 May; 158():138-145. PubMed ID: 33636228
[TBL] [Abstract][Full Text] [Related]
20. Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.
Thon N; Thorsteinsdottir J; Eigenbrod S; Schüller U; Lutz J; Kreth S; Belka C; Tonn JC; Niyazi M; Kreth FW
J Neurol; 2017 Feb; 264(2):350-358. PubMed ID: 27921166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
